The Antidote - Spring 2014
Taking a look at "pharmerging" markets and the resurgence in UK biotech IPOs
We can barely keep up with what is, or is speculated to be, happening in the sector with big pharma. In this edition, we comment on some of the M&A activity and await with interest what may occur over the next weeks and months.
We also look at why the Far East continues to hold so much promise for the sector, particularly in China and Singapore and we look at what may be the start of a resurgence for UK biotech IPOs.
As you may also be aware, CMS today merged with leading Scottish law firm, Dundas & Wilson, and we are delighted to welcome Carina Healy as a member of our core Lifesciences group. Carina brings a wealth of experience to the group and we very much look forward to introducing you to Carina over the coming months.